fosamprenavir has been researched along with atropine in 1 studies
Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) |
---|---|---|---|---|---|
174 | 55 | 37 | 26,711 | 1,259 | 1,697 |
Protein | Taxonomy | fosamprenavir (IC50) | atropine (IC50) |
---|---|---|---|
cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 21.41 | |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.012 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.0067 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.0007 | |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0009 | |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0015 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0021 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.354 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.012 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fosamprenavir and atropine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |